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Abstract 
Background: The mitochondrial DNA (mtDNA) seems to influence in a large number of diseases, including HIV 
infection. Moreover, there is a substantial inter‑individual variability in the CD4+ recovery in HIV‑infected patients on 
combination antiretroviral therapy (cART). Our study aimed to analyze the association between mtDNA haplogroups 
and CD4+ recovery in HIV‑infected patients on cART.
Methods: This is a retrospective study of 324 naïve cART patients with CD4+ < 200 cells/mm3, who were followed‑
up during 24 months after initiating cART. All patients had undetectable HIV viral load during the follow‑up. Besides, 
we included 141 healthy controls. MtDNA genotyping was performed by using Sequenom’s MassARRAY platform. The 
primary outcome variable was the slope of CD4+ recovery. Patients were stratified into two groups by the median 
slope value of CD4+ (9.65 CD4+ cells/mm3/month). Logistic regression analyses were performed to calculate the 
odds of CD4+ recovery according to mtDNA haplogroups.
Results: Our study included European HIV‑infected patients within the N macro‑cluster. The baseline values of CD4+ 
T‑cells were similar between groups of patients stratified by the P50th of the slope of CD4+ T‑cells recovery. Patients 
in the low CD4+ T‑cells recovery group were older (p = 0.001), but this variable was included in the multivariate 
models. When we analyzed the frequencies of mtDNA haplogroups, no significant differences between HIV‑infected 
individuals and healthy controls were found. We did not find any significant association between mtDNA haplogroups 
and the slope of CD4+ T‑cells recovery by linear regression analysis. However, Patients carrying haplogroup H had a 
higher odds of having a better CD4+ recovery (> 9.65 CD4+ cells/mm3/month) than patients without haplogroup 
H (p = 0.032). The adjusted logistic regression showed that patients carrying haplogroup H had a higher likelihood 
of achieving a CD4+ recovery > 9.65 CD4+ cells/mm3/month [adjusted odds ratio (aOR) = 1.75 (95% CI = 1.04; 2.95); 
p = 0.035].
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Background
The human immunodeficiency virus (HIV) infects and 
destroys the CD4+ T cell, promoting a continuous loss 
of CD4+ T cells that leads to immunodeficiency, oppor-
tunistic diseases, and death [1, 2]. The cART reduces the 
plasma HIV-RNA to undetectable levels and restores 
immunologic function, decreasing clinical progression 
and prolonging life [3]. However, despite suppression of 
HIV replication, a fraction of cART-treated patients fail 
to reconstitute CD4+ T-cell numbers sufficiently [4].
Mitochondrial dysfunction is related to acquired 
immune deficiency syndrome (AIDS) progression, in 
which there is mitochondrial DNA (mtDNA) deple-
tion, increased reactive oxygen species (ROS) formation, 
antioxidant enzyme deficiency, and increased oxidative 
damage in patients with accelerated AIDS disease [5]. 
Additionally, mitochondrial toxicity due to nucleoside 
reverse transcriptase inhibitors may contribute to severe 
side effects observed in HIV-infected individuals on 
combination antiretroviral therapy (cART) [5].
Variations in mtDNA sequence are associated with 
several disorders [6], including HIV infection [5]. The 
combinations of mtDNA polymorphisms define mito-
chondrial haplogroups, which have a well-defined phy-
logeny among human populations [7]. In European 
Caucasians (N macro-cluster), people stratify in 4 clus-
ter or major-haplogroups (HV, U, JT, and IWX) and sev-
eral main haplogroups (H, V, pre-V, J, T, U, W, X, I) [7]. 
In European HIV-infected patients, mtDNA haplogroup 
has been associated with viroimmunological parameters, 
metabolic alterations, and AIDS progression [5, 8–10]. 
To our knowledge, only a previous study of our group has 
reported data about European mtDNA haplogroups and 
immune recovery in a cohort of HIV-infected patients 
starting cART with CD4+ count < 350 cells/mm3 in a 
tertiary hospital in Madrid (Spain) [11]. In the current 
multicentric study, we analyzed the association between 
European haplogroups and CD4+ T-cell recovery in 
naïve HIV-infected patients starting cART with CD4+ 
count < 200 cells/mm3 collected throughout the Spanish 
national territory.
Methods
Study population
We performed a retrospective study in 324 Euro-
pean HIV-infected patients receiving cART and 141 
healthy controls of age and sex similar to patients. The 
Institutional Ethics Committee approved the study in 
concordance with the Declaration of Helsinki. All sub-
jects provided informed consent to participate in the 
study.
The Spanish HIV BioBank of the CoRIS and the AIDS 
Research Institute IrsiCaixa-HIVACAT, Institut de 
Recerca en Ciències de la Salut Germans Trias i Pujol 
(Barcelona, Spain) provided patients. Epidemiological 
and clinical data were collected from medical records. 
The inclusion criteria were: (1) naïve for cART at inclu-
sion in the cohort; (2) plasma HIV-RNA > 200 copies/
mL; (3) starting cART with CD4+ counts < 200 cells/µL; 
(4) complete viral suppression (plasma HIV-RNA < 50 
copies/mL) for two years after starting cART; (5) regu-
lar follow up of CD4+ counts and plasma HIV-RNA for 
two years after starting cART; (6) Individuals who were 
within the European N macro-haplogroup.
DNA genotyping
The Spanish National Genotyping Center (CeGen; http://
www.cegen .org/) genotyped DNA samples by using the 
 iPLEX® Gold technology and Agena Bioscience’s Mas-
sARRAY platform (San Diego, CA, USA). We selected 14 
mtDNA polymorphisms within N macro-cluster [7, 11], 
to stratify patients by major-haplogroups or cluster (HV, 
IWX, U, and JT) and haplogroups (H, V, pre-V, J, T, I, W 
and X) (see Additional file 1).
Outcome variables
The primary outcome variable was the slope of CD4+ 
T-cells (summary measure) during 2 years of follow-up. 
Patients were stratified in two groups by the median 
value of CD4+ T-cells slope in the whole population of 
patients (9.65 CD4+ cells/mm3/month): high CD4+ 
recovery (≥ 9.65 CD4+ cells/mm3/month) and low 
CD4+ recovery (< 9.65 CD4+ cells/mm3/month).
Statistical analysis
Statistical analysis was performed with SPSS 22.0 soft-
ware (SPSS INC, Chicago, IL, USA). All tests were 
two-tailed with p-values ≤ 0.05 considered significant. 
Categorical data and proportions were analyzed by using 
Chi squared test or Fisher´s exact test. Mann–Whitney 
U test was used to compare data between independent 
groups when the variables were continuous.
Generalized Linear Models (GLM) with a gamma dis-
tribution (log-link) were used to evaluate the differences 
Conclusions: European mitochondrial haplogroup H was associated with the improved CD4+ recovery in HIV‑
infected patients starting cART with CD4+ < 200 cells/mm3.
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in the slope of CD4+ T-cells recovery (continuous vari-
able). Logistic regression models were used to calculate 
the odds of higher or lower CD4+ recovery according 
to mtDNA haplogroups, one for each haplogroup evalu-
ated. The multivariate regression tests were adjusted by 
the main clinical characteristics at baseline: gender, age, 
length of HIV-infection, baseline CD4+ cells/mm3, HIV 
transmission route, hepatitis C and hepatitis B coinfec-
tion, and type of cART regimen.
Results
Characteristics of the study population
Our study included European HIV-infected patients 
within the N macro-cluster [7]. From the total Spanish 
AIDS Research Network (CoRIS) and AIDS Research 
Institute IrsiCaixa-HIVACAT Cohorts (n = 6160 HIV-
patients) we only selected the HIV-patients meeting the 
inclusion criteria described in Methods section (n = 418). 
Lastly, 94 individuals were excluded from the analy-
sis either because genotyping was not valid (n = 13) or 
because the haplogroup did not belong to the N-cluster 
or to a European haplogroup (n = 81). Thus, the final 
analysis included 324 patients (see Additional file  2). 
The baseline characteristics of patients stratified by the 
P50th of the slope of CD4+ T-cells recovery are shown in 
Table 1. Patients in the low CD4+ T-cells recovery group 
were older (p = 0.001), but this variable was included in 
the multivariate models. Moreover, the baseline values 
of CD4+ T-cells were similar between groups, but after 
2 years of successful cART, the values CD4+ T-cells were 
higher in patients with high CD4+ recovery than low 
CD4+ recovery [513 (418.4; 636.5) vs. 274 (176.7; 365.6); 
p < 0.001].
Characteristics of mtDNA haplogroups
When we analyzed the frequencies of mtDNA haplo-
groups, no significant differences between HIV-infected 
individuals and healthy controls were found (Fig.  1). 
Note that healthy controls were similar to HIV-infected 
patients regarding gender and age. Moreover, the cluster 
IWX and minor haplogroups V, pre-V, I, X, and W were 
discarded for the genetic association study because these 
mtDNA haplogroups had low frequencies (< 5%) in HIV 
infected patients (Fig.  1). Thus, the genetic association 
tests were performed on the clusters HV, U, and JT; and 
on the haplogroups H, J, and T.
mtDNA haplogroups and CD4+ T‑cell recovery
We did not find any significant association between 
mtDNA haplogroups and the slope of CD4+ T-cells 
recovery by linear regression analysis (Table  2). How-
ever, we found significant values when patients were 
stratified by the P50th of the slope of CD4+ T-cells 
recovery (Fig.  2). We found higher frequency of H 
Table 1 Baseline clinical and epidemiological characteristics of HIV infected patients
IDU intravenous drug users, HIV human immunodeficiency virus, cART combination antiretroviral therapy, PI HIV protease inhibitor, NNRTI non-nucleoside analogue 
HIV reverse transcriptase inhibitor
Statistical: Values were expressed as absolute number (percentage) and median (percentile 25; percentile 75). Significant differences are shown in bold. p-values were 
calculated by Chi square and Mann–Whitney tests
Characteristics All patients HIV groups
Low CD4+ recovery High CD4+ recovery p‑value
No. 324 162 162
Male 264 (81.5%) 138 (85.2%) 126 (77.8%) 0.086
Age (years) 41.0 (34.7; 49.2) 43 (36.4; 51.3) 39.9 (33.8; 46.5) 0.001
Time since HIV diagnosis (years) 1 (1.0; 1.0) 1 (1.0; 2.0) 1 (1.0; 1.0) 0.117
CD4+ cell count at baseline (cells/μL) 105 (41; 159) 93.3 (37.5;147) 114.5 (41.5;165) 0.230
Hepatitis C infection 29 (8.9%) 16 (9.9%) 13 (8.0%) 0.559
Hepatitis B infection 14 (4.3%) 8 (4.9%) 6 (3.7%) 0.585
cART regimen
 PI‑based 103 (31.8%) 45 (28.0%) 58 (35.8%) 0.469
 NNRTI‑based 165 (51.1%) 88 (54.7%) 77 (47.5%)
 PI+ NNRTI‑based 38 (11.8%) 20 (12.4%) 18 (11.1%)
 Others 17 (5.3%) 8 (5.0%) 9 (5.6%)
HIV transmission route
 IDU 51 (17.1%) 30 (20.8%) 21 (13.4%) 0.219
 Homosexual transmission 152 (50.8%) 68 (47.2%) 84 (54.2%)
 Heterosexual transmission 96 (32.1%) 46 (31.9%) 50 (32.3%)
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haplogroup in patients with high CD4+ recovery 
(≥ 9.65 CD4+ cells/mm3/month) (p = 0.032). On the 
other hand, in multivariate analysis adjusted by the 
main clinical characteristics at baseline (see statisti-
cal analysis section), patients with haplogroup H had 
higher odds of having a better CD4+ T-cell recovery 
than patients without haplogroup H [adjusted odds 
ratio (aOR) = 1.75 (95% CI = 1.04; 2.95); p = 0.035]. No 
significant associations were found for the others hap-
logroups (Fig. 3; full description in Additional file 3).
Discussion
In this study, haplogroup H was related to better CD4+ 
T-cells counts recovery in HIV-infected patients start-
ing cART with low CD4 counts and followed during the 
first 24  months after initiating cART. This association 
was found both in the univariate and in the multivariate 
analysis adjusted by the most important baseline charac-
teristics. However, we did not find any association when 
the continuous outcome measure (slope of CD4+ T-cells 
recovery) was used, possibly because there is no linear 
relationship between the analyzed variables.
Fig. 1 Frequencies of mtDNA haplogroups in HIV infected patients and healthy controls. Statistical: p‑values were calculated by Chi square 
test. *The percentages of mtDNA haplogroups, for both HIV and HC groups, do not add to 100% because the cluster U was not stratified in 
minor‑haplogroups. HIV human immunodeficiency virus, HC healthy controls
Table 2 Summary of  the  slopes of  CD4+ T-cells recovery (cells/mm3/month) for  each mtDNA haplogroup 
and the relationship between them in HIV-infected patients who started combined antiretroviral therapy
HIV human immunodeficiency virus, aAMR adjusted arithmetic mean ratio, CI confidence interval
Statistical: * Values were expressed as median (cells/mm3/month) (percentile 25; percentile 75). p-values were calculated by Mann–Whitney tests. ** Values were 
expressed as adjusted arithmetic mean ratio (aAMR) and 95% of confidence interval (95% CI) of the slopes of CD4+ T-cells recovery (cells/mm3/month). p-values were 
calculated by Generalized Linear Models test with a normal distribution (log-link). These regressions were adjusted by the most important clinical and epidemiological 
characteristics (gender, age, length of HIV-infection, baseline CD4+ cells/mm3, HIV transmission route related to IDU, hepatitis C and hepatitis B coinfection, and type 
of cART regimen)
Mt DNA haplogroups Unadjusted analysis* Adjusted analysis**
No Yes p‑value aAMR (95% CI) p‑value
Clusters or major haplogroups
 HV 9.1 (5.5; 14) 10 (6.4; 14.7) 0.288 0.98 (0.86; 1.13) 0.839
 U 9.8 (6.2; 14.1) 9.1 (5.1; 13.9) 0.321 0.91 (0.77; 1.08) 0.300
 JT 9.8 (6.2; 14) 9.2 (5.6; 13.6) 0.765 1.12 (0.94; 1.33) 0.205
Haplogroups
 H 9.1 (5.6; 13.7) 10.2 (6.9; 14.1) 0.075 1.04 (0.91; 1.21) 0.544
 J 9.8 (6.2; 14) 8.8 (5.2; 12.2) 0.522 1.07 (0.86; 1.32) 0.537
 T 9.6 (6.1; 14) 9.7 (6.8; 14.2) 0.735 1.17 (0.90; 1.51) 0.225
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The data found in this study confirm the positive influ-
ence of European haplogroup H on CD4+ T-cells count 
recovery in cART-treated patients, which was previously 
described by our group in a different cohort [11]. In addi-
tion to the influence of haplogroup H, in this previous 
article of Guzmán-Fulgencio et al. [11], we also found a 
worse CD4+ recovery in patients with haplogroup J and 
T. However, we did not observe any significant associa-
tion for haplogroups J and T in the current study. The 
small sample size could explain this discrepancy in these 
haplogroups, which may have impaired the ability to 
detect less robust associations. However, we must also 
consider other factors. On the one hand, the article of 
Guzmán-Fulgencio et  al. [11] studied a cohort of HIV-
infected patients provided by a tertiary referral hospital 
center (Spain), with baseline CD4+ values < 350 cells/
mm3, and followed during at least 24  months. On the 
other hand, we now analyzed a cohort of HIV-infected 
patients provided by a large number of hospitals spread 
throughout Spain (a sample more representative of Span-
ish population), with baseline CD4+ values < 200 cells/
mm3 (a more restricted criteria), and followed during the 
first 24 months after starting cART (the same follow-up 
in all patients). Moreover, the type of statistical analysis 
applied was different in our previous study. In the article 
of Guzmán-Fulgencio et  al. [11], a survival analysis was 
performed with CD4+ > 500  cells/mm3 as the primary 
outcome, whereas in the present study, we calculated the 
slope of CD4+ T-cells count for each patient and com-
pared groups by logistic regression analysis.
Moreover, mtDNA haplogroups in other cohort 
have also been related to CD4+ T-cells recovery in 
HIV-infected patients who started cART. Grady et  al. 
found that African L2 haplogroup was associated with 
decreased odds of CD4+ T-cells recovery after cART 
(CD4+ count change of ≥ 100 cells/mm3 and median 
CD4+ T-cell increases at 48  weeks of follow-up) in the 
AIDS Clinical Trials Group study 384 [12]. However, 
they did not find any significant association with Euro-
pean mitochondrial haplogroups in non-Hispanic white 
participants.
In the present study, the age of HIV-infected patients 
with worse CD4+ T-cells recovery was higher than 
patients with better CD4+ T-cells recovery, which 
Fig. 2 Percentage of HIV‑infected patients according to mtDNA haplogroups and CD4+ T cell recovery during the follow‑up. Statistical: p‑values 
were calculated by Chi squared test or Fisher’s exact test
Fig. 3 Summary of the association between mtDNA haplogroups 
and CD4+ T cell recovery in HIV‑infected patients who started 
combination antiretroviral therapy. Statistical: Logistic regression 
models were used to calculate the odds of higher or lower CD4+ 
recovery according to mtDNA haplogroups, one for each haplogroup 
evaluated. These regressions were adjusted by the most important 
clinical and epidemiological characteristics (gender, age, length of 
HIV‑infection, baseline CD4+ cells/mm3, HIV transmission route, 
hepatitis C and hepatitis B coinfection, and cART regimen). aOR 
adjusted odds ratio, 95% CI 95% of confidence interval
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could have had a negative impact since a poorer CD4+ 
T-cell counts recovery has been found in older HIV-
infected patients starting cART [13]. However, we think 
that only 3  years of difference between groups is not 
relevant in adults of 35–45  years. In fact, we included 
the age in the multivariate analysis, and the significant 
association between haplogroup H and CD4+ T-cells 
recovery was maintained.
Variants in mtDNA which are not silent may have 
an essential role in adaptation to environmental con-
ditions, by modulating specific mitochondrial func-
tions [14]. Thus, the differences found in mtDNA 
haplogroups distribution among the different groups 
of patients in our study may be because haplogroup H 
is related to higher activity in the electron transport 
chain, producing higher levels of ATP and ROS than 
other haplogroups [15–17], increasing the immune 
response against HIV infection [9]. Furthermore, ROS 
production may lead to an up-regulation of antioxidant 
defenses without causing severe immune damage [18], 
contributing to proper immune function, ensuring con-
trol of HIV replication and, in turn, decreasing oxida-
tive stress and apoptosis [19, 20]. Additionally, a higher 
degree of energetic efficiency could have a substantial 
impact on HIV infection since the efficiency of the 
metabolism regulate T-cell function and susceptibility 
to infection [21]. The functional role of mtDNA haplo-
groups is controversial, but it is possible that the effects 
of mitochondrial haplogroups may emerge under spe-
cial conditions such as CD4+ T-cells recovery in HIV-
infected patients starting cART. However, we could not 
perform functional experiments to determinate the 
energetic efficiency in isolated mitochondria of T-cells 
from patients.
Nowadays or in the future, our results may have an 
impact on clinical practice in those cases where cART 
starts with very low CD4+ T-cells. cART should begin 
in all HIV-infected patients, regardless of the CD4+ 
T-cells count in order to decrease the risk of HIV trans-
mission and prevent AIDS-related illness [22]. How-
ever, late presentation for HIV care is a significant and 
persistent issue throughout the world [23–25], includ-
ing developed countries with health systems with good 
access to health services [24]. Late presenters have 
delayed initiation of cART, CD4 values below 350 cells/
mm3 and below 200 cells/mm3 in many cases [26], and 
higher risk of AIDS progression and death [27]. The 
initiation of cART with very low CD4+ T-cell counts 
is consistently associated with poorer outcomes of 
cART [28]. Thus, our data could provide information to 
improve the management of HIV-infected patients with 
poorer prognosis of CD4+ T-cells recovery.
Study limitations
Our study has some limitations that we should take into 
account to make a correct interpretation of the results. 
Firstly, this is a retrospective study and, therefore, the 
case record is selected a priori from patients surviv-
ing long enough to yield sufficient follow-up (at least 
24 months after cART). Secondly, the sample size is lim-
ited, particularly in some haplogroups, which may have 
impaired the ability to detect less robust associations. 
Thirdly, although our results suggest that some vari-
ants in mtDNA may influence CD4+ T-cell recovery, it 
would be necessary to perform functional ROS and ATP 
measurement in the patients to provide additional con-
firmatory data. Fourthly, this study was carried out on 
Caucasian patients, and our conclusions are only truly 
applicable to this population.
Conclusions
In conclusion, European haplogroup H was associated 
with the improved CD4+ recovery in HIV-infected 
patients starting cART with CD4+ < 200 cells/mm3. This 
finding could be useful to understand the host genetic 
factors involved in the immune recovery of cART-treated 
patients. Additionally, it also may help to improve the 
management of patients with a poorer prognosis of 
immune recovery.
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